Oncolytic Virus Therapy Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncolytic Virus Therapy Market 

5.1. COVID-19 Landscape: Oncolytic Virus Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncolytic Virus Therapy Market, By Virus Type

8.1. Oncolytic Virus Therapy Market, by Virus Type

8.1.1. Adenovirus

8.1.1.1. Market Revenue and Forecast

8.1.2. Herpes Simplex Virus

8.1.2.1. Market Revenue and Forecast

8.1.3. Vaccinia Virus- fastest Growing

8.1.3.1. Market Revenue and Forecast

8.1.4. Reovirus

8.1.4.1. Market Revenue and Forecast

8.1.5. Measles Virus

8.1.5.1. Market Revenue and Forecast

8.1.6. Newcastle Disease Virus (NDV)

8.1.6.1. Market Revenue and Forecast

8.1.7. Vesicular Stomatitis Virus (VSV)

8.1.7.1. Market Revenue and Forecast

8.1.8. Other engineered/native viral platforms

8.1.8.1. Market Revenue and Forecast

Chapter 9. Global Oncolytic Virus Therapy Market, By Modification / Engineering

9.1. Oncolytic Virus Therapy Market, by Modification / Engineering

9.1.1. Unmodified / Wild-type oncolytic viruses

9.1.1.1. Market Revenue and Forecast

9.1.2. Genetically engineered

9.1.2.1. Market Revenue and Forecast

9.1.3. Armed oncolytics

9.1.3.1. Market Revenue and Forecast

9.1.4. Retargeted / tumor-selective tropism engineering

9.1.4.1. Market Revenue and Forecast

9.1.5. Combination vectors

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Oncolytic Virus Therapy Market, By Mechanism of Action 

10.1. Oncolytic Virus Therapy Market, by Mechanism of Action

10.1.1. Direct oncolysis

10.1.1.1. Market Revenue and Forecast

10.1.2. Immunogenic cell death / immune stimulation

10.1.2.1. Market Revenue and Forecast

10.1.3. Virotherapy-mediated gene delivery

10.1.3.1. Market Revenue and Forecast

10.1.4. Combination multimodal mechanisms

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Oncolytic Virus Therapy Market, By Indication / Cancer Type

11.1. Oncolytic Virus Therapy Market, by Indication / Cancer Type

11.1.1. Melanoma- Dominating 1

11.1.1.1. Market Revenue and Forecast

11.1.2. Head & Neck Cancers

11.1.2.1. Market Revenue and Forecast

11.1.3. Lung Cancer (NSCLC, SCLC)

11.1.3.1. Market Revenue and Forecast

11.1.4. Analog, MEMS and Others

11.1.4.1. Market Revenue and Forecast

11.1.5. Colorectal Cancer

11.1.5.1. Market Revenue and Forecast

11.1.6. Hepatocellular Carcinoma (HCC)

11.1.6.1. Market Revenue and Forecast

11.1.7. Pancreatic Cancer

11.1.7.1. Market Revenue and Forecast

11.1.8. Ovarian & Gynecological Cancers

11.1.8.1. Market Revenue and Forecast

11.1.9. Hematological Malignancies

11.1.9.1. Market Revenue and Forecast

11.1.10. Other solid tumors

11.1.10.1. Market Revenue and Forecast

Chapter 12. Global Oncolytic Virus Therapy Market, By End-User

12.1. Oncolytic Virus Therapy Market, by End-User

12.1.1. Large pharmaceutical companies / Big biotech

12.1.1.1. Market Revenue and Forecast

12.1.2. Small & mid-sized biotech companies / startups

12.1.2.1. Market Revenue and Forecast

12.1.3. Contract research organizations (CROs) / CDMOs

12.1.3.1. Market Revenue and Forecast

12.1.4. Academic & research institutes / hospitals

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Oncolytic Virus Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Virus Type

13.1.2. Market Revenue and Forecast, by Modification / Engineering

13.1.3. Market Revenue and Forecast, by Mechanism of Action

13.1.4. Market Revenue and Forecast, by Indication / Cancer Type

13.1.5. Market Revenue and Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Virus Type

13.1.6.2. Market Revenue and Forecast, by Modification / Engineering

13.1.6.3. Market Revenue and Forecast, by Mechanism of Action

13.1.6.4. Market Revenue and Forecast, by Indication / Cancer Type

13.1.6.5. Market Revenue and Forecast, by End-User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Virus Type

13.1.7.2. Market Revenue and Forecast, by Modification / Engineering

13.1.7.3. Market Revenue and Forecast, by Mechanism of Action

13.1.7.4. Market Revenue and Forecast, by Indication / Cancer Type

13.1.7.5. Market Revenue and Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Forecast, by Virus Type

13.2.2. Market Revenue and Forecast, by Modification / Engineering

13.2.3. Market Revenue and Forecast, by Mechanism of Action

13.2.4. Market Revenue and Forecast, by Indication / Cancer Type  

13.2.5. Market Revenue and Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Virus Type

13.2.6.2. Market Revenue and Forecast, by Modification / Engineering

13.2.6.3. Market Revenue and Forecast, by Mechanism of Action

13.2.7. Market Revenue and Forecast, by Indication / Cancer Type  

13.2.8. Market Revenue and Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Virus Type

13.2.9.2. Market Revenue and Forecast, by Modification / Engineering

13.2.9.3. Market Revenue and Forecast, by Mechanism of Action

13.2.10. Market Revenue and Forecast, by Indication / Cancer Type

13.2.11. Market Revenue and Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Virus Type

13.2.12.2. Market Revenue and Forecast, by Modification / Engineering

13.2.12.3. Market Revenue and Forecast, by Mechanism of Action

13.2.12.4. Market Revenue and Forecast, by Indication / Cancer Type

13.2.13. Market Revenue and Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Virus Type

13.2.14.2. Market Revenue and Forecast, by Modification / Engineering

13.2.14.3. Market Revenue and Forecast, by Mechanism of Action

13.2.14.4. Market Revenue and Forecast, by Indication / Cancer Type

13.2.15. Market Revenue and Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Forecast, by Virus Type

13.3.2. Market Revenue and Forecast, by Modification / Engineering

13.3.3. Market Revenue and Forecast, by Mechanism of Action

13.3.4. Market Revenue and Forecast, by Indication / Cancer Type

13.3.5. Market Revenue and Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Virus Type

13.3.6.2. Market Revenue and Forecast, by Modification / Engineering

13.3.6.3. Market Revenue and Forecast, by Mechanism of Action

13.3.6.4. Market Revenue and Forecast, by Indication / Cancer Type

13.3.7. Market Revenue and Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Virus Type

13.3.8.2. Market Revenue and Forecast, by Modification / Engineering

13.3.8.3. Market Revenue and Forecast, by Mechanism of Action

13.3.8.4. Market Revenue and Forecast, by Indication / Cancer Type

13.3.9. Market Revenue and Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Virus Type

13.3.10.2. Market Revenue and Forecast, by Modification / Engineering

13.3.10.3. Market Revenue and Forecast, by Mechanism of Action

13.3.10.4. Market Revenue and Forecast, by Indication / Cancer Type

13.3.10.5. Market Revenue and Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Virus Type

13.3.11.2. Market Revenue and Forecast, by Modification / Engineering

13.3.11.3. Market Revenue and Forecast, by Mechanism of Action

13.3.11.4. Market Revenue and Forecast, by Indication / Cancer Type

13.3.11.5. Market Revenue and Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Forecast, by Virus Type

13.4.2. Market Revenue and Forecast, by Modification / Engineering

13.4.3. Market Revenue and Forecast, by Mechanism of Action

13.4.4. Market Revenue and Forecast, by Indication / Cancer Type

13.4.5. Market Revenue and Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Virus Type

13.4.6.2. Market Revenue and Forecast, by Modification / Engineering

13.4.6.3. Market Revenue and Forecast, by Mechanism of Action

13.4.6.4. Market Revenue and Forecast, by Indication / Cancer Type

13.4.7. Market Revenue and Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Virus Type

13.4.8.2. Market Revenue and Forecast, by Modification / Engineering

13.4.8.3. Market Revenue and Forecast, by Mechanism of Action

13.4.8.4. Market Revenue and Forecast, by Indication / Cancer Type

13.4.9. Market Revenue and Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Virus Type

13.4.10.2. Market Revenue and Forecast, by Modification / Engineering

13.4.10.3. Market Revenue and Forecast, by Mechanism of Action

13.4.10.4. Market Revenue and Forecast, by Indication / Cancer Type

13.4.10.5. Market Revenue and Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Virus Type

13.4.11.2. Market Revenue and Forecast, by Modification / Engineering

13.4.11.3. Market Revenue and Forecast, by Mechanism of Action

13.4.11.4. Market Revenue and Forecast, by Indication / Cancer Type

13.4.11.5. Market Revenue and Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Virus Type

13.5.2. Market Revenue and Forecast, by Modification / Engineering

13.5.3. Market Revenue and Forecast, by Mechanism of Action

13.5.4. Market Revenue and Forecast, by Indication / Cancer Type

13.5.5. Market Revenue and Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Virus Type

13.5.6.2. Market Revenue and Forecast, by Modification / Engineering

13.5.6.3. Market Revenue and Forecast, by Mechanism of Action

13.5.6.4. Market Revenue and Forecast, by Indication / Cancer Type

13.5.7. Market Revenue and Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Virus Type

13.5.8.2. Market Revenue and Forecast, by Modification / Engineering

13.5.8.3. Market Revenue and Forecast, by Mechanism of Action

13.5.8.4. Market Revenue and Forecast, by Indication / Cancer Type

13.5.8.5. Market Revenue and Forecast, by End-User

Chapter 14. Company Profiles

14.1. Replimune Group Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Oncolytics Biotech Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Sorrento Therapeutics, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. PsiOxus Therapeutics Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Transgene SA

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. SillaJen, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Lokon Pharma AB

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. CG Oncology Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. DNAtrix

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Targovax

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms